FDA approves Retatrutide this year?
As of Tue, 20 Oct 2026 09:50:36 UTC, Polymarket traders price Yes (2.5%). The market has $595K in volume and closes on Fri, 01 Jan 2027.
Updated:
Current odds
| Outcome | Chance | Yes price | No price |
|---|---|---|---|
| Yes | 2.5% | 2.5¢ | 97.5¢ |
Market details
- Venue: Polymarket
- Volume: $595K
- Liquidity: $5K
- Closes:
Resolution rules
Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals p…
Sources
Related markets
- Skin cancer vaccine BLA submitted by...?
- U.S. enacts AI safety bill before 2027?
- Which Millennium Prize Problem will AI solve next?
- How many more Millennium Prize Problems will AI solve in 2026?
- Which math problems will AI solve in 2026?
- Which companies will be acquired before 2027?
DOXA is a liquidity aggregator for prediction markets that compares odds and depth across Polymarket, Kalshi and others and routes each trade for best execution with an AI assistant.